Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer treatment, has scheduled its Q3 2024 financial results and business updates conference call for November 13, 2024 at 8:00 a.m. Eastern Time. Investors can access the call via domestic (833-255-2826) or international (412-317-0689) dial-in numbers. A webcast will be available on the company's website, with a replay accessible for approximately 90 days following the presentation.

11/06/2024 - 08:00 AM

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When will Mersana Therapeutics (MRSN) report Q3 2024 earnings?

Mersana Therapeutics will report its Q3 2024 financial results on Wednesday, November 13, 2024, at 8:00 a.m. Eastern Time.

How can investors access Mersana Therapeutics' Q3 2024 earnings call?

Investors can access the call by dialing 833-255-2826 (domestic) or 412-317-0689 (international), or via webcast on the Investors & Media section of www.mersana.com.